Publications
Partners
South Africa is among the countries that will participate in the phase II clinical trial of a tuberculosis (TB) drug believed to assist in shortening and improving treatment for patients with both drug-sensitive and drug-resistant TB.
According to an article in The Lancet Microbe, the phase II clinical TB drug trial comes after successfully implementing the phase 1 clinical trial of the drug, now referred to as TBAJ-876.
The article states that the drug is a diarylquinoline, a TB treatment and category of antibiotic that targets a key enzyme of the tuberculosis bacteria involved in energy production.
